Unfavourable medical events occurring before investigational product administration should be handled how?

Boost your GCP E6 (R3) exam readiness. Improve your understanding with engaging, insightful questions. Test yourself with hints and detailed explanations. Prepare effectively!

Multiple Choice

Unfavourable medical events occurring before investigational product administration should be handled how?

In safety reporting, what a protocol requires governs how events are handled. Events that occur before the investigational product is given still matter for the safety profile of the trial—they’re part of the subject’s safety data and can influence eligibility and interpretation of later events. Because of that, these pre-dose events should be recorded and managed according to the protocol’s instructions and, if the protocol requires it, reported to the sponsor for safety oversight. They aren’t automatically reported as SAEs in all cases, and they shouldn’t be ignored; the reporting depends on whether the protocol specifies that pre-dose events must be reported and, if they meet SAE criteria, how promptly that reporting should occur. This is why the best approach is to handle them as you would any safety data: consider them and report to the sponsor if the protocol requires.

In safety reporting, what a protocol requires governs how events are handled. Events that occur before the investigational product is given still matter for the safety profile of the trial—they’re part of the subject’s safety data and can influence eligibility and interpretation of later events. Because of that, these pre-dose events should be recorded and managed according to the protocol’s instructions and, if the protocol requires it, reported to the sponsor for safety oversight. They aren’t automatically reported as SAEs in all cases, and they shouldn’t be ignored; the reporting depends on whether the protocol specifies that pre-dose events must be reported and, if they meet SAE criteria, how promptly that reporting should occur. This is why the best approach is to handle them as you would any safety data: consider them and report to the sponsor if the protocol requires.

More practice questions